Vaxxas has received a manufacturing licence from Australia’s Therapeutic Goods Administration (TGA) for its high-density microarray patch (HD-MAP) for clinical studies at a biomedical facility in ...

Vaxxas Chair Sarah Meibusch said, "The TGA manufacturing licence marks a significant milestone for Vaxxas as we progress toward commercialising our HD-MAP technology. By reducing cold-chain ...

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the publication of data supporting the effective use of its high-density microarray patch ...

Recently published data generated by researchers at The University of Queensland and Vaxxas shows effective delivery of a nucleic acid-based COVID-19 vaccine in a preclinical animal study utilizing ...

The clinical study aims to evaluate a vaccine for avian influenza A (H7N9) delivered by Vaxxas’ high-density microarray patch (HD-MAP), and is funded by the United States government as a potential ...

The MarketWatch News Department was not involved in the creation of this content. -- Multi-center Phase I clinical study will evaluate the safety and tolerability of a monovalent strain of avian ...

Deptartment of Immunotechnology, BMC D13, Lund University, SE-221 84 Lund, Sweden, CREATE Health, BMC D13, Lund University, SE-221 84 Lund, Sweden, and Bioinvent International AB, SE-223 70 Lund, ...

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced a publication in the journal Vaccine entitled “Vaccine microarray patch self-administration ...

CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the publication of clinical trial ...

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the publication of clinical trial data demonstrating the potential of Vaxxas’ high-density ...